Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort

Research output: Contribution to journalJournal articlepeer-review

Standard

Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort. / Groot, Jonathan; Petersen, Tanja G; Suren, Pål; Brantsæter, Anne Lise; Uldall, Peter; Martinussen, Torben; Granström, Charlotta; Olsen, Sjurdur F; Wilcox, Allen J; Strandberg-Larsen, Katrine.

In: The American Journal of Clinical Nutrition, Vol. 115, No. 2, nqab351, 2022, p. 397–406.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Groot, J, Petersen, TG, Suren, P, Brantsæter, AL, Uldall, P, Martinussen, T, Granström, C, Olsen, SF, Wilcox, AJ & Strandberg-Larsen, K 2022, 'Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort', The American Journal of Clinical Nutrition, vol. 115, no. 2, nqab351, pp. 397–406. https://doi.org/10.1093/ajcn/nqab351

APA

Groot, J., Petersen, T. G., Suren, P., Brantsæter, A. L., Uldall, P., Martinussen, T., Granström, C., Olsen, S. F., Wilcox, A. J., & Strandberg-Larsen, K. (2022). Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort. The American Journal of Clinical Nutrition, 115(2), 397–406. [nqab351]. https://doi.org/10.1093/ajcn/nqab351

Vancouver

Groot J, Petersen TG, Suren P, Brantsæter AL, Uldall P, Martinussen T et al. Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort. The American Journal of Clinical Nutrition. 2022;115(2):397–406. nqab351. https://doi.org/10.1093/ajcn/nqab351

Author

Groot, Jonathan ; Petersen, Tanja G ; Suren, Pål ; Brantsæter, Anne Lise ; Uldall, Peter ; Martinussen, Torben ; Granström, Charlotta ; Olsen, Sjurdur F ; Wilcox, Allen J ; Strandberg-Larsen, Katrine. / Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort. In: The American Journal of Clinical Nutrition. 2022 ; Vol. 115, No. 2. pp. 397–406.

Bibtex

@article{73afdf25cb5c442195412dba9265b834,
title = "Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort",
abstract = "BACKGROUND: Folate prevents neural tube defects and may play a role in some neurodevelopmental disorders.OBJECTIVE(S): To investigate whether higher intakes of periconceptional or midpregnancy folate as recommended were associated with a reduced risk of offspring cerebral palsy (CP).METHODS: We included participants from the Nordic collaboration cohort consisting of mother-child dyads in the Danish National Birth Cohort and the Norwegian Mother, Father and Child Cohort Study (MOBAND-CP). A total of 190 989 live-born children surviving the first year of life were included. Missing covariate data were multiply imputed. Our exposures were defined as any or no folic acid supplementation in gestational weeks (GWs) -4 to 8 (periconceptional), GWs 9 to 12, and -4 to 12, and supplemental, dietary, and total folate during midpregnancy (GWs 22 to 25). CP overall and the unilateral and bilateral spastic subtypes, as well as CP with low or moderate/high gross motor function impairment were our outcomes of interest.RESULTS: Periconceptional folic acid supplementation was not associated with CP (adjusted odds ratio (aOR) 1.02; 95% confidence intervals (CI) 0.82, 1.28). However, supplementation in GWs 9 to 12 was associated with a reduced risk of CP (aOR 0.74; 0.57, 0.96), and inverse associations were indicated for both the unilateral (aOR 0.68; 0.46, 1.02) and bilateral (aOR 0.70; 0.49, 1.02) spastic subtypes, although not statistically significant. Supplemental or dietary folate in midpregnancy alone were not associated with CP. Strong inverse associations were observed with low gross motor function impairment (aOR 0.49; 0.29, 0.83), while for unilateral CP the aOR was 0.63 (0.34, 1.22) for intakes of ≥ 500 compared to ≤ 199 dietary folate equivalents/day during midpregnancy.CONCLUSIONS: Our findings suggested that folate intakes in GWs 9 to 12 and midpregnancy were associated with a lower risk of CP, while no association was observed for periconceptional supplementation.",
author = "Jonathan Groot and Petersen, {Tanja G} and P{\aa}l Suren and Brants{\ae}ter, {Anne Lise} and Peter Uldall and Torben Martinussen and Charlotta Granstr{\"o}m and Olsen, {Sjurdur F} and Wilcox, {Allen J} and Katrine Strandberg-Larsen",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.",
year = "2022",
doi = "10.1093/ajcn/nqab351",
language = "English",
volume = "115",
pages = "397–406",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "2",

}

RIS

TY - JOUR

T1 - Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort

AU - Groot, Jonathan

AU - Petersen, Tanja G

AU - Suren, Pål

AU - Brantsæter, Anne Lise

AU - Uldall, Peter

AU - Martinussen, Torben

AU - Granström, Charlotta

AU - Olsen, Sjurdur F

AU - Wilcox, Allen J

AU - Strandberg-Larsen, Katrine

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.

PY - 2022

Y1 - 2022

N2 - BACKGROUND: Folate prevents neural tube defects and may play a role in some neurodevelopmental disorders.OBJECTIVE(S): To investigate whether higher intakes of periconceptional or midpregnancy folate as recommended were associated with a reduced risk of offspring cerebral palsy (CP).METHODS: We included participants from the Nordic collaboration cohort consisting of mother-child dyads in the Danish National Birth Cohort and the Norwegian Mother, Father and Child Cohort Study (MOBAND-CP). A total of 190 989 live-born children surviving the first year of life were included. Missing covariate data were multiply imputed. Our exposures were defined as any or no folic acid supplementation in gestational weeks (GWs) -4 to 8 (periconceptional), GWs 9 to 12, and -4 to 12, and supplemental, dietary, and total folate during midpregnancy (GWs 22 to 25). CP overall and the unilateral and bilateral spastic subtypes, as well as CP with low or moderate/high gross motor function impairment were our outcomes of interest.RESULTS: Periconceptional folic acid supplementation was not associated with CP (adjusted odds ratio (aOR) 1.02; 95% confidence intervals (CI) 0.82, 1.28). However, supplementation in GWs 9 to 12 was associated with a reduced risk of CP (aOR 0.74; 0.57, 0.96), and inverse associations were indicated for both the unilateral (aOR 0.68; 0.46, 1.02) and bilateral (aOR 0.70; 0.49, 1.02) spastic subtypes, although not statistically significant. Supplemental or dietary folate in midpregnancy alone were not associated with CP. Strong inverse associations were observed with low gross motor function impairment (aOR 0.49; 0.29, 0.83), while for unilateral CP the aOR was 0.63 (0.34, 1.22) for intakes of ≥ 500 compared to ≤ 199 dietary folate equivalents/day during midpregnancy.CONCLUSIONS: Our findings suggested that folate intakes in GWs 9 to 12 and midpregnancy were associated with a lower risk of CP, while no association was observed for periconceptional supplementation.

AB - BACKGROUND: Folate prevents neural tube defects and may play a role in some neurodevelopmental disorders.OBJECTIVE(S): To investigate whether higher intakes of periconceptional or midpregnancy folate as recommended were associated with a reduced risk of offspring cerebral palsy (CP).METHODS: We included participants from the Nordic collaboration cohort consisting of mother-child dyads in the Danish National Birth Cohort and the Norwegian Mother, Father and Child Cohort Study (MOBAND-CP). A total of 190 989 live-born children surviving the first year of life were included. Missing covariate data were multiply imputed. Our exposures were defined as any or no folic acid supplementation in gestational weeks (GWs) -4 to 8 (periconceptional), GWs 9 to 12, and -4 to 12, and supplemental, dietary, and total folate during midpregnancy (GWs 22 to 25). CP overall and the unilateral and bilateral spastic subtypes, as well as CP with low or moderate/high gross motor function impairment were our outcomes of interest.RESULTS: Periconceptional folic acid supplementation was not associated with CP (adjusted odds ratio (aOR) 1.02; 95% confidence intervals (CI) 0.82, 1.28). However, supplementation in GWs 9 to 12 was associated with a reduced risk of CP (aOR 0.74; 0.57, 0.96), and inverse associations were indicated for both the unilateral (aOR 0.68; 0.46, 1.02) and bilateral (aOR 0.70; 0.49, 1.02) spastic subtypes, although not statistically significant. Supplemental or dietary folate in midpregnancy alone were not associated with CP. Strong inverse associations were observed with low gross motor function impairment (aOR 0.49; 0.29, 0.83), while for unilateral CP the aOR was 0.63 (0.34, 1.22) for intakes of ≥ 500 compared to ≤ 199 dietary folate equivalents/day during midpregnancy.CONCLUSIONS: Our findings suggested that folate intakes in GWs 9 to 12 and midpregnancy were associated with a lower risk of CP, while no association was observed for periconceptional supplementation.

U2 - 10.1093/ajcn/nqab351

DO - 10.1093/ajcn/nqab351

M3 - Journal article

C2 - 34687208

VL - 115

SP - 397

EP - 406

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 2

M1 - nqab351

ER -

ID: 286624302